# First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)

> **NCT07285889** · PHASE1,PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 35 (estimated)

## Conditions studied

- Acute Graft Versus Host Disease

## Interventions

- **DRUG:** Gecacitinib (also known as Jaktinib) combined glucocorticoids

## Key facts

- **NCT ID:** NCT07285889
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-03
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07285889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07285889, "First-Line Jaktinib for Acute Graft-Versus-Host Disease (aGVHD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07285889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*